Drug Profile
UK 357903
Alternative Names: UK-357903Latest Information Update: 05 Sep 2006
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Erectile dysfunction
Most Recent Events
- 05 Sep 2006 Discontinued - Phase-II for Erectile dysfunction in Europe (unspecified route)
- 16 Feb 2001 Phase-II clinical trials for Erectile dysfunction in Europe (Unknown route)
- 23 Jun 2000 Pfizer has merged with Warner-Lambert